Filing Flows › Cardiff Oncology (CRDF) › Q3 2025
Cardiff Oncology (CRDF) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 6, 2025
Cardiff Oncology (CRDF) reported revenue of $120K for the third quarter 2025 (Q3 2025), -27% from a year earlier and -0.8% from the quarter before.
Cardiff Oncology, Q3 2025: revenue $120K (-27% year over year), net loss $11.3M, operating cash flow −$10.8M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $120K | -0.8% | -27% |
| Operating profit | −$12.0M | — | — |
| Net earnings | −$11.3M | — | — |
| Operating cash flow | −$10.8M | — | — |
What changed
Revenue was $120K in Q3 2025, down 27% year over year and down 1% from the previous quarter.
Operating costs exceeded revenue by $12.0M, an operating margin of -9978.3%. Total costs fell 5% while revenue fell 27%. The fastest-growing cost line was SG&A (+25%). The quarter ended with a net loss of $11.3M, narrower than the previous quarter's $13.9M loss.
Operating cash flow was −$10.8M. Non-cash charges added back $89K of depreciation and $1.4M of share-based compensation. Working capital and other items used $1.0M. Capital expenditures of $18K exceeded it, leaving free cash flow of −$10.9M.
Questions
What was Cardiff Oncology's revenue in the third quarter 2025?
Cardiff Oncology (CRDF) reported revenue of $120K for the third quarter 2025 (Q3 2025), -27% from a year earlier and -0.8% from the quarter before.
Source: Cardiff Oncology 10-Q on SEC EDGAR.